Table 1.
Baseline characteristics of patients with BCP-ALL (N = 164)
| Characteristics | N (%) |
|---|---|
| Age (yr), median (range) |
4 |
| <1 |
0 |
| 1-9 |
136 (82.9) |
| ≥10 |
28 (17.1) |
| Gender |
|
| Male |
104 (63.4) |
| Female |
60 (36.6) |
| WBC (109/L) |
|
| <50 |
136 (82.9) |
| ≥50 |
28 (17.1) |
| Treatment group |
|
| SR |
62 (37.8) |
| MR |
81 (49.4) |
| HR |
21 (12.8) |
| Fusion genes |
|
|
TEL-AML1 |
41 (25.0) |
|
E2A-PBX1 |
16 (9.8) |
|
BCR-ABL |
8 (4.9) |
|
MLL-AF4 |
1 (0.6) |
| CNS involvement |
2 (1.2) |
| Event |
|
| Relapse |
16 (9.8) |
| Isolated BM |
13 (7.9) |
| Isolated CNS |
1 (0.6) |
| Isolated testis |
2 (1.2) |
| Death* |
4 (2.4) |
| Prednisone response |
|
| Good |
162 (98.8) |
| Poor | 2 (1.2) |
BCP-ALL, B-cell precursor ALL; WBC, white blood cell count; SR, standard-risk; MR, medium-risk; HR, high-risk; BM, bone marrow; CNS, central nervous system. *4 patients died of severe infections during induction.